COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE PRODUCT
AbbVie Veliparib Biodrugs/ Drugs Cancer Brain cancer, Breast, ovarian and colorectal Cancer, Non-small-cell lung carcinoma (NSCLC)and Small Cell Lung Cancer (SCLC ), Triple-negative breast cancer (TNBC), solid tumors 3PhIII Veliparib
Therapeutic area: Cancer
AbbVie ABBV-8E12 Biodrugs/ Drugs Central Nervous System Alzheimer 2PhII ABBV-8E12
Therapeutic area: Central Nervous System
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABT-066 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasis, Psoriatic arthritis, Crohn disease 3PhIII ABT-066
Therapeutic area: Autoimmune & Inflammation
AbbVie ABT-122 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasic arthritis 2PhII ABT-122
Therapeutic area: Autoimmune & Inflammation
AbbVie Rova-T Biodrugs/ Drugs Cancer Solid tumor 3PhIII Rova-T
Therapeutic area: Cancer
AbbVie SLV245-CREON Biodrugs/ Drugs Metabolic / Endocrinology Cystic fibrosis 3PhIII SLV245-CREON
Therapeutic area: Metabolic / Endocrinology
AbbVie Humira (adalimumab) Biodrugs/ Drugs Autoimmune & Inflammation Hidradenitis Suppurativa / Peripheral Spondyloarthritis / Uveitis / Ulcerative colitis / Chron Disease / Enthesitis paediatric / AR / Psoriasis 4Reg. Humira (adalimumab)
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-176 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABBV-176
Therapeutic area: Cancer
AbbVie ABT-414 Biodrugs/ Drugs Cancer Relapsed GBM / Incipient GBM 3PhIII ABT-414
Therapeutic area: Cancer
AbbVie Atrasentan Biodrugs/ Drugs Kidney and Genitourinary system Diabetic Nephropathy 3PhIII Atrasentan
Therapeutic area: Kidney and Genitourinary system
AbbVie ABBV-838 Biodrugs/ Drugs Cancer Multiple myeloma 1PhI ABBV-838
Therapeutic area: Cancer
AbbVie ABBV-221 Biodrugs/ Drugs Cancer EGFR (Epidermal growth factor receptor) 1PhI ABBV-221
Therapeutic area: Cancer
AbbVie Elagolix Biodrugs/ Drugs Women´s health Endometriosis 3PhIII Elagolix
Therapeutic area: Women´s health
AbbVie ABV-085 Biodrugs/ Drugs Cancer Solid tumor 1PhI ABV-085
Therapeutic area: Cancer
AbbVie ABT-981 Biodrugs/ Drugs Analgesia & Pain
Autoimmune & Inflammation
Knee Osteoarthritis 2PhII ABT-981
Therapeutic area: Analgesia & Pain / Autoimmune & Inflammation
AbbVie ABT-199/GDC0199 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Multiple mieloma 3PhIII ABT-199/GDC0199
Therapeutic area: Blood and Lymphatic systems / Cancer
AbbVie ABT-SLV187 Biodrugs/ Drugs Central Nervous System Parkinson 4Reg. ABT-SLV187
Therapeutic area: Central Nervous System
AbbVie ABBV-181 Biodrugs/ Drugs Cancer Solid tumor 2PhII ABBV-181
Therapeutic area: Cancer
AbbVie ABT-494 Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid Arthritis, Crohn Disease 3PhIII ABT-494
Therapeutic area: Autoimmune & Inflammation
AbbVie HCV Interferon-Free Combination (genotype 1) Biodrugs/ Drugs Infections haepatitis C 3PhIII HCV Interferon-Free Combination (genotype 1)
Therapeutic area: Infections
AbbVie ABBV-621 Biodrugs/ Drugs Cancer Hematology 1PhI ABBV-621
Therapeutic area: Cancer
Amgen AMG 334 Biodrugs/ Drugs Central Nervous System Migraine 2PhII AMG 334
Therapeutic area: Central Nervous System
Amgen Etelcalcetide Biodrugs/ Drugs Metabolic / Endocrinology Secondary Hyperparathyroidism 4Reg. Etelcalcetide
Therapeutic area: Metabolic / Endocrinology
Amgen Conatumumab Biodrugs/ Drugs Cancer Various cancer types 2PhII Conatumumab
Therapeutic area: Cancer
Amgen Romosozumab Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Postmenopausal osteoporosis 3PhIII Romosozumab
Therapeutic area: Musculoskeletal Disorders / Women´s health
Amgen AMG 181 Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn´s disease 2PhII AMG 181
Therapeutic area: Autoimmune & Inflammation / Digestive System
Amgen Denosumab Biodrugs/ Drugs Musculoskeletal Disorders Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer 4Reg. Denosumab
Therapeutic area: Musculoskeletal Disorders
Amgen Denosumab Biodrugs/ Drugs Cancer Giant cell tumour of the bone 2PhII Denosumab
Therapeutic area: Cancer
Amgen Brodalumab Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Psoriatic arthritis 4Reg. Brodalumab
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Amgen Omecantiv mecarbil Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure 3PhIII Omecantiv mecarbil
Therapeutic area: Cardiovascular and circulatory systems
Amgen Brodalumab Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Psoriasis 4Reg. Brodalumab
Therapeutic area: Autoimmune & Inflammation / Dermatology
Amgen Romiplostim Biodrugs/ Drugs Blood and Lymphatic systems Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) 4Reg. Romiplostim
Therapeutic area: Blood and Lymphatic systems
Amgen Rilotumumab Biodrugs/ Drugs Cancer Various cancer types 3PhIII Rilotumumab
Therapeutic area: Cancer
Amgen Darbepoetin alfa Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Treatment of symptomatic anemia associated with chronic renal failure in adults / Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies 3PhIII Darbepoetin alfa
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Evolocumab Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia 4Reg. Evolocumab
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Amgen Blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute lymphoblastic leukaemia 4Reg. Blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Talimogene laherparepvec Biodrugs/ Drugs Cancer Malignant melanoma 4Reg. Talimogene laherparepvec
Therapeutic area: Cancer
Amgen Trebananib Biodrugs/ Drugs Cancer Ovarian Cancer 3PhIII Trebananib
Therapeutic area: Cancer
Amgen Cinacalcet Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT 4Reg. Cinacalcet
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Amgen AMG 337 Biodrugs/ Drugs Cancer Gastric cancer 2PhII AMG 337
Therapeutic area: Cancer
Biogen Spain Daclizumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 3PhIII Daclizumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain anti-TWEAK Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Lupus Nephritis 2PhII anti-TWEAK
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Biogen Spain antiLingo Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 2PhII antiLingo
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain Natalizumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Secondary Progressive Multiple Sclerosis 2PhII Natalizumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain antiLingo Biodrugs/ Drugs Ophthalmology and optometry Optic Neuritis 2PhII antiLingo
Therapeutic area: Ophthalmology and optometry
Biogen Spain IFN ß 1a pgilated Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. IFN ß 1a pgilated
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Biogen Spain BG-12 Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. BG-12
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Celgene Ozanimod Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis Relapsing multiple sclerosis 3PhIII Ozanimod
Therapeutic area: Autoimmune & Inflammation
Celgene CC-90006 Biodrugs/ Drugs Autoimmune & Inflammation Autoinmune disorders 1PhI CC-90006
Therapeutic area: Autoimmune & Inflammation
Celgene Ozanimod Biodrugs/ Drugs Autoimmune & Inflammation Crohn`s disease 2PhII Ozanimod
Therapeutic area: Autoimmune & Inflammation
Celgene AG-881 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute Myeloid Leukemia (AML) Glioma 1PhI AG-881
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene SOTATERCEPT (ACE-011) Biodrugs/ Drugs Autoimmune & Inflammation Chronic kidney disease 2PhII SOTATERCEPT (ACE-011)
Therapeutic area: Autoimmune & Inflammation
Celgene CD19 CAR-T (JCAR017) Biodrugs/ Drugs Blood and Lymphatic systems Aggressive large B-cell lymphoma: Relapsed/refractory 1PhI CD19 CAR-T (JCAR017)
Therapeutic area: Blood and Lymphatic systems
Celgene BCMA CAR-T (bb2121) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) 1PhI BCMA CAR-T (bb2121)
Therapeutic area: Blood and Lymphatic systems
Celgene CC-220 Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) relapsed/refractory 1PhI CC-220
Therapeutic area: Blood and Lymphatic systems
Celgene ISTODAX® (romidepsin) Biodrugs/ Drugs Blood and Lymphatic systems Peripheral T-cell lymphoma:First-line 3PhIII ISTODAX® (romidepsin)
Therapeutic area: Blood and Lymphatic systems
Celgene Citarinostat (ACY-241) Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) relapsed/refractory 1PhI Citarinostat (ACY-241)
Therapeutic area: Blood and Lymphatic systems
Celgene CC-90001 Biodrugs/ Drugs Autoimmune & Inflammation Fibrosis 1PhI CC-90001
Therapeutic area: Autoimmune & Inflammation
Celgene REVLIMID® (lenalidomide) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse large B-cell lymphoma (ABC subtype): First line Indolent lymphoma: relapsed/refractory Follicular lymphoma: first line 3PhIII REVLIMID® (lenalidomide)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma 1PhI CC 486
Therapeutic area: Blood and Lymphatic systems
Celgene LSD1 Inhibitor: CC-90011 Biodrugs/ Drugs Cancer Solid tumors 1PhI LSD1 Inhibitor: CC-90011
Therapeutic area: Cancer
Celgene PD-L1 Inhibitor:durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Multiple Myeloma (MM) Chronic Lymphocytic Leukemia (CLL) No-Hodgkin Lymphoma (NHL) 1PhI PD-L1 Inhibitor:durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS): lower-risk Post-induction AML maintenance 3PhIII CC-486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene ISTODAX® (romidepsin) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Peripheral T-cell lymphoma: relapsed/refractory (Japan) 2PhII ISTODAX® (romidepsin)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene OTEZLA® (apremilast) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII OTEZLA® (apremilast)
Therapeutic area: Autoimmune & Inflammation
Celgene PDA-002 Biodrugs/ Drugs Others Diabetic foot ulcers Diabetic peripheral neuropathy 2PhII PDA-002
Therapeutic area: Others
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Breast: Metastatic Non-small cell lung: Advanced Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure 2PhII CC 486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Morgensen (GED-0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Ulcerative colitis 2PhII Morgensen (GED-0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene PNK-007 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) Multiple Myeloma (MM) 1PhI PNK-007
Therapeutic area: Blood and Lymphatic systems
Celgene OTEZLA® (Apremilast) Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Ankylosing spondylitis Behcets disease 3PhIII OTEZLA® (Apremilast)
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Celgene AG-221 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 3PhIII AG-221
Therapeutic area: Blood and Lymphatic systems
Celgene RPC4046 Biodrugs/ Drugs Autoimmune & Inflammation Eosinophilic esophagitis 2PhII RPC4046
Therapeutic area: Autoimmune & Inflammation
Celgene ABRAXANE® Biodrugs/ Drugs Cancer Pancreatic:Adjuvant 3PhIII ABRAXANE®
Therapeutic area: Cancer
Celgene AG-120 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 1PhI AG-120
Therapeutic area: Blood and Lymphatic systems
Celgene PD-L1 Inhibitor: durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) 2PhII PD-L1 Inhibitor: durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene VIDAZA® (azacitidine for injection) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute myeloid laeukemia (AML) (>30% blasts) 3PhIII VIDAZA® (azacitidine for injection)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CAR-T (JCAR15) Biodrugs/ Drugs Blood and Lymphatic systems ALL( Accute Lymphoblastic Leukemia) 2PhII CAR-T (JCAR15)
Therapeutic area: Blood and Lymphatic systems
Celgene Anti-CD47 Antibody: CC-90002 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) Solid Tumors 1PhI Anti-CD47 Antibody: CC-90002
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-122 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoma: Diffuse large B-Cell & Indolent lymphoma: relapsed/refractory Hepatocellular carcinoma Multiple Myeloma Chronic Lymphocytic Leukemia (CLL) 1PhI CC-122
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene Mongersen (GED 0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII Mongersen (GED 0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene Luspatercept (ACE-536) Biodrugs/ Drugs Blood and Lymphatic systems
Others
Myelodisplastic Syndromes (MDS) Beta-thalassemia 3PhIII Luspatercept (ACE-536)
Therapeutic area: Blood and Lymphatic systems / Others
Celgene CC-90009 Biodrugs/ Drugs Blood and Lymphatic systems Acute Myeloid Leukemia (AML) 1PhI CC-90009
Therapeutic area: Blood and Lymphatic systems
Celgene PPM Pleiotropic Pathway Modifier: CC-122 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Gliobastoma Multiforme Hepatocellular carcinoma 2PhII PPM Pleiotropic Pathway Modifier: CC-122
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-220 Biodrugs/ Drugs Autoimmune & Inflammation Systemic lupus erythematosus 2PhII CC-220
Therapeutic area: Autoimmune & Inflammation
Genzyme Alemtuzumab Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. Alemtuzumab
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Genzyme Eliglustat Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Lysosomal Diseases; Gaucher Disease 4Reg. Eliglustat
Therapeutic area: Genetic Diseases and Dysmorphic syndromes / Metabolic / Endocrinology
Genzyme Aubagio® (teriflunomida) Biodrugs/ Drugs Autoimmune & Inflammation
Central Nervous System
Multiple Sclerosis 4Reg. Aubagio® (teriflunomida)
Therapeutic area: Autoimmune & Inflammation / Central Nervous System
Gilead Sciences GS-6615 (late sodium current inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Ventricular tachycardia / Ventricular fibrillation 2PhII GS-6615 (late sodium current inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC Biodrugs/ Drugs Infections Chronic HBV infection 3PhIII Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area: Infections
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Pulmonary arterial hypertension 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences Emtricitabine/Rilpivirine /Tenofovir alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Emtricitabine/Rilpivirine /Tenofovir alafenamide STR
Therapeutic area: Infections
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area: Infections
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area: Infections
Gilead Sciences Momelotinib Biodrugs/ Drugs Cancer Pancreatic cancer 2PhII Momelotinib
Therapeutic area: Cancer
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Digestive System Nonalcoholic steatohaepatitis 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Digestive System
Gilead Sciences Simtuzumab Biodrugs/ Drugs Digestive System Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis 2PhII Simtuzumab
Therapeutic area: Digestive System
Gilead Sciences Simtuzumab Biodrugs/ Drugs Respiratory and Pulmonary system Idiopathic pulmonary fibrosis 2PhII Simtuzumab
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences Momelotinib Biodrugs/ Drugs Blood and Lymphatic systems Myelofibrosis 3PhIII Momelotinib
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Ranolazine Biodrugs/ Drugs Cardiovascular and circulatory systems Incomplete revascularization post-PCI (Percutaneous Coronary Intervention) 3PhIII Ranolazine
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences GS-5806 (fusion inhibitor) Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Respiratory syncytial virus 2PhII GS-5806 (fusion inhibitor)
Therapeutic area: Infections / Respiratory and Pulmonary system
Gilead Sciences Idelalisib Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Frontline chronic lymphocytic laeukemia, frontline/indolent non-Hodgkin's lymphoma, relapsed refractory CLL 3PhIII Idelalisib
Therapeutic area: Blood and Lymphatic systems / Cancer
LILLY insulin-Fc/Dula Biodrugs/ Drugs Metabolic / Endocrinology Diabetes 1PhI insulin-Fc/Dula
Therapeutic area: Metabolic / Endocrinology
LILLY Ramucirumab Biodrugs/ Drugs Cancer 2nd line hepatocellular carcinoma 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY N3pG-AB Monoclonal Antibody Biodrugs/ Drugs Central Nervous System Alzheimer 1PhI N3pG-AB Monoclonal Antibody
Therapeutic area: Central Nervous System
LILLY Ramucirumab Biodrugs/ Drugs Cancer 1st line EGFR positive NSCLC 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY Tau Antibody Biodrugs/ Drugs Central Nervous System Alzheimer 1PhI Tau Antibody
Therapeutic area: Central Nervous System
LILLY IL-23 antibody Biodrugs/ Drugs Autoimmune & Inflammation ulcerative colitis 2PhII IL-23 antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Angiopoietin 2 Mab cancer Biodrugs/ Drugs Cancer cancer 1PhI Angiopoietin 2 Mab cancer
Therapeutic area: Cancer
LILLY Galcanezumab Biodrugs/ Drugs Analgesia & Pain prevention of chronic and episodic migraine 3PhIII Galcanezumab
Therapeutic area: Analgesia & Pain
LILLY PCSK9 Monoclonal Antibody Biodrugs/ Drugs Cardiovascular and circulatory systems cardiovascular disease 2PhII PCSK9 Monoclonal Antibody
Therapeutic area: Cardiovascular and circulatory systems
LILLY CSF-1R Monoclonal Antibody Biodrugs/ Drugs Cancer cancer 1PhI CSF-1R Monoclonal Antibody
Therapeutic area: Cancer
LILLY Ultra-rapid Insulin Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 2PhII Ultra-rapid Insulin
Therapeutic area: Metabolic / Endocrinology
LILLY FGFR3-ADC Biodrugs/ Drugs Cancer cancer 1PhI FGFR3-ADC
Therapeutic area: Cancer
LILLY CXCR4 Peptide Antagonist Biodrugs/ Drugs Cancer cancer 2PhII CXCR4 Peptide Antagonist
Therapeutic area: Cancer
LILLY Oxyntomodulin Biodrugs/ Drugs Metabolic / Endocrinology diabetes 1PhI Oxyntomodulin
Therapeutic area: Metabolic / Endocrinology
LILLY Emibetuzumab Biodrugs/ Drugs Cancer NSCLC 2PhII Emibetuzumab
Therapeutic area: Cancer
LILLY PD-L1 Antibody Biodrugs/ Drugs Cancer cancer 1PhI PD-L1 Antibody
Therapeutic area: Cancer
LILLY BAFF/ IL-17 bispecific antibody Biodrugs/ Drugs Autoimmune & Inflammation immune diseases 1PhI BAFF/ IL-17 bispecific antibody
Therapeutic area: Autoimmune & Inflammation
LILLY AB42 Antibody Alzheimer´s Biodrugs/ Drugs Central Nervous System Alzheimer 1PhI AB42 Antibody Alzheimer´s
Therapeutic area: Central Nervous System
LILLY CXCR1/2 Ligands Antibody Biodrugs/ Drugs Autoimmune & Inflammation immune diseases 1PhI CXCR1/2 Ligands Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Ixekizumab Biodrugs/ Drugs Autoimmune & Inflammation axial spondyloarthritis 3PhIII Ixekizumab
Therapeutic area: Autoimmune & Inflammation
LILLY IL-21 Antibody Biodrugs/ Drugs Autoimmune & Inflammation immune diseases 1PhI IL-21 Antibody
Therapeutic area: Autoimmune & Inflammation
LILLY Galcanezumab Biodrugs/ Drugs Analgesia & Pain cluster headache and migraine prevention of chronic and episodic migraine 3PhIII Galcanezumab
Therapeutic area: Analgesia & Pain
LILLY GIP/GLP-1 Co-agonist peptide Biodrugs/ Drugs Metabolic / Endocrinology diabetes 1PhI GIP/GLP-1 Co-agonist peptide
Therapeutic area: Metabolic / Endocrinology
LILLY Ramucirumab Biodrugs/ Drugs Cancer second line bladder cancer 3PhIII Ramucirumab
Therapeutic area: Cancer
LILLY no name Biodrugs/ Drugs Metabolic / Endocrinology hypoglycemia 1PhI no name
Therapeutic area: Metabolic / Endocrinology
LILLY Ramucirumab Biodrugs/ Drugs Cancer first-line gastric cancer 3PhIII Ramucirumab
Therapeutic area: Cancer
Merck KGaA Evofosfamida Biodrugs/ Drugs Cancer
Dermatology
Digestive System
Pancreas, cancer, sarcoma 4Reg. Evofosfamida
Therapeutic area: Cancer / Dermatology / Digestive System
Merck KGaA Pimasertib Biodrugs/ Drugs Cancer Colorectal Cancer, Pancreas, Melanoma, solid tumours and ovarian cancer 4Reg. Pimasertib
Therapeutic area: Cancer
Merck KGaA Avelumab Biodrugs/ Drugs Cancer Several types of cancer 3PhIII Avelumab
Therapeutic area: Cancer
Merck KGaA Abituzumab Biodrugs/ Drugs Cancer Colorectal Cancer, Prostate cancer, solid tumours 2PhII Abituzumab
Therapeutic area: Cancer
Merck KGaA Atacicept Biodrugs/ Drugs Autoimmune & Inflammation Autoinmune disease 2PhII Atacicept
Therapeutic area: Autoimmune & Inflammation
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Doravirine Biodrugs/ Drugs Infections HIV Infection 3PhIII Doravirine
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer 20 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Odanacatib Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium 3PhIII Odanacatib
Therapeutic area: Musculoskeletal Disorders / Women´s health
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Elbasvir/Grazoprevir Biodrugs/ Drugs Infections Chronic Hepatitis C 3PhIII Elbasvir/Grazoprevir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer 10 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Raltegravir Biodrugs/ Drugs Infections HIV Infection 3PhIII Raltegravir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Ph 3 1L Study of Pembrolizumab +/- Ipilimumab in NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer PD-L1 Strong Metastatic Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Etonogestrel+ Estradiol (vaginal ring) Biodrugs/ Drugs Women´s health Contraception 3PhIII Etonogestrel+ Estradiol (vaginal ring)
Therapeutic area: Women´s health
MSD Pembrolizumab Biodrugs/ Drugs Cancer Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with recurrent ovarian cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Fosaprepitant Biodrugs/ Drugs Cancer Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy 3PhIII Fosaprepitant
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer "Phase 3 trial of first line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer" 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Triple-Negative Breast Cancer (mTNBC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Etonogestrel+ Estradiol (vaginal ring) Biodrugs/ Drugs Women´s health Contraception 3PhIII Etonogestrel+ Estradiol (vaginal ring)
Therapeutic area: Women´s health
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Sitagliptin Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes 3PhIII Sitagliptin
Therapeutic area: Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Anacetrapib Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease 3PhIII Anacetrapib
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
MSD Gardasil 9 Biodrugs/ Drugs Infections Prevention of HPV infection with Gardasil 9 in adult women 27-45 compared to young adult women (16-26) 3PhIII Gardasil 9
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Doravirine Biodrugs/ Drugs Infections HIV Infection 3PhIII Doravirine
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced/Unresectable or Metastatic Urothelial Cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD MK3682 Biodrugs/ Drugs Infections Chronic Hepatitis C 2PhII MK3682
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Vacuna Vaccines Infections Staphylococcus aureus Vaccine 3PhIII Vacuna
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer In combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD V920 Vaccines Infections Three consistency lot doses and high dose of rVSV-ZEBOV-GiP (V920 ebola vaccine) in Healthy Adults 3PhIII V920
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) in Advanced Renal Cell Carcinoma (RCC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Suvorexant Biodrugs/ Drugs Others Primary Insomnia 3PhIII Suvorexant
Therapeutic area: Others
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with lenalidomide and dexamethasone in subjects Multiple Myeloma 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Biodrugs/ Drugs Infections V503 in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds) 3PhIII Gardasil 9
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Rotavirus Vaccine Vaccines Infections Rotavirus Vaccine 3PhIII Rotavirus Vaccine
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Biodrugs/ Drugs Infections 2-dose regimen of V503, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds) 3PhIII Gardasil 9
Therapeutic area: Infections
MSD LAG3 Biodrugs/ Drugs Cancer 6 Select Advanced Solid Tumors 1PhI LAG3
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia 1PhI Posaconazole
Therapeutic area: Infections
MSD V114 Biodrugs/ Drugs Infections Prevention of Pneumococal infection with V114 comparing to Prevnar 13 in healthy infants 2PhII V114
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Letermovir Biodrugs/ Drugs Infections Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients 3PhIII Letermovir
Therapeutic area: Infections
MSD GLP-1R agonist Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes 2PhII GLP-1R agonist
Therapeutic area: Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. 3PhIII Posaconazole
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Rituximab Versus Rituximab in Subjects With Relapsed Follicular Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Inhibitor of human β-site APP cleaving enzyme (BACE1) Biodrugs/ Drugs Central Nervous System Alzheimer’s Disease 3PhIII Inhibitor of human β-site APP cleaving enzyme (BACE1)
Therapeutic area: Central Nervous System
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma (1st line) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Inactivated VZV Vaccine Vaccines Blood and Lymphatic systems
Cancer
Adult Patients with Solid Tumor or Hematologic Malignancy 3PhIII Inactivated VZV Vaccine
Therapeutic area: Blood and Lymphatic systems / Cancer
MSD BET Inhibitor Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI BET Inhibitor
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil in Subjects with Advanced/Metastatic Esophageal Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
Novo Nordisk Pharma AM833 (amilyn analogue) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI AM833 (amilyn analogue)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma G53L (glucagon analogue/liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI G53L (glucagon analogue/liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma PYY1562 (analogue peptid YY) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI PYY1562 (analogue peptid YY)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma OI338GT (oral insulin) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 2PhII OI338GT (oral insulin)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegAsp (combination insulin degludec + insulin aspart) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 and type 1 4Reg. IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegLira (combination insulin degludec + liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 4Reg. IDegLira (combination insulin degludec + liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 in paediatric population 3PhIII Liraglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide 3mg Biodrugs/ Drugs Metabolic / Endocrinology Obesity 4Reg. Liraglutide 3mg
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Nonacog beta pegol Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia B 4Reg. Nonacog beta pegol
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Turoctocog alfa Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 4Reg. Turoctocog alfa
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma N8-GP (glycopegylated recombinant FVIII) Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII N8-GP (glycopegylated recombinant FVIII)
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Insulin LA287 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Insulin LA287
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide NASH Biodrugs/ Drugs Metabolic / Endocrinology Non-alcoholic steatohepatitis 1PhI Semaglutide NASH
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide type 1 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 3PhIII Liraglutide type 1
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Prandial Bioedge Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Prandial Bioedge
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Faster-acting insulin aspart (FIAsp) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and type 2 4Reg. Faster-acting insulin aspart (FIAsp)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Monoclonal antibody anti Il-21 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 2PhII Monoclonal antibody anti Il-21
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Somapacitan(Long-acting growth hormone) Biodrugs/ Drugs Metabolic / Endocrinology Growth hormone deficiency 3PhIII Somapacitan(Long-acting growth hormone)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma OI320GT (oral insulin) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI OI320GT (oral insulin)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Oral semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Oral semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Concizumab Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A and B 1PhI Concizumab
Therapeutic area: Blood and Lymphatic systems
Roche XOLAIR Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Dermatitis (Allergic Contact) 3PhIII XOLAIR
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche BITOPERTIN Biodrugs/ Drugs Central Nervous System Schizophrenia 3PhIII BITOPERTIN
Therapeutic area: Central Nervous System
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII PDL1 MAB
Therapeutic area: Cancer
Roche OX40 Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI OX40
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 2PhII LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII APITOLISIB
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI APITOLISIB
Therapeutic area: Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche OCRELIZUMAB Biodrugs/ Drugs Central Nervous System Musculoskeletal Disorders 3PhIII OCRELIZUMAB
Therapeutic area: Central Nervous System
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Systemic lupus erythematosus 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII PICTILISIB
Therapeutic area: Cancer
Roche PLGF MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PLGF MAB
Therapeutic area: Cancer
Roche NEORECORMON Biodrugs/ Drugs Blood and Lymphatic systems Anaemia in neoplastic disease 2PhII NEORECORMON
Therapeutic area: Blood and Lymphatic systems
Roche BASIMGLURANT Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes Fragile X Syndrome 2PhII BASIMGLURANT
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI APITOLISIB
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Peripheral Vascular Diseases 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche ALEGLITAZAR Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII ALEGLITAZAR
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Other + unspecif. types of non-Hodgkin's lymphoma 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII PICTILISIB
Therapeutic area: Cancer
Roche PATECLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII PATECLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche CMV ANTI Biodrugs/ Drugs Infections Cytomegaloviral disease 2PhII CMV ANTI
Therapeutic area: Infections
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Metabolic / Endocrinology Thyrotoxicosis (hyperthyroidism) 3PhIII ACTEMRA
Therapeutic area: Metabolic / Endocrinology
Roche ALEGLITAZAR Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII ALEGLITAZAR
Therapeutic area: Metabolic / Endocrinology
Roche PEGASYS Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII PEGASYS
Therapeutic area: Infections
Roche BRAF KIN INH (2) Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI BRAF KIN INH (2)
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche SEMBRAGILINE Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII SEMBRAGILINE
Therapeutic area: Central Nervous System
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 2PhII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CRENEZUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII CRENEZUMAB
Therapeutic area: Central Nervous System
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of brain 3PhIII AVASTIN
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant melanoma of skin 3PhIII COBIMETINIB
Therapeutic area: Cancer
Roche TAMIFLU Biodrugs/ Drugs Infections Influenza 3PhIII TAMIFLU
Therapeutic area: Infections
Roche CEA IL2V Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA IL2V
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII VANUCIZUMAB
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII TARCEVA
Therapeutic area: Cancer
Roche DANOPREVIR Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII DANOPREVIR
Therapeutic area: Infections
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of prostate 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Irritable bowel syndrome 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII AVASTIN
Therapeutic area: Cancer
Roche TASPOGLUTIDE Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII TASPOGLUTIDE
Therapeutic area: Metabolic / Endocrinology
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI TASELISIB
Therapeutic area: Cancer
Roche ALPHA7 NIC AGO Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ALPHA7 NIC AGO
Therapeutic area: Central Nervous System
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of pancreas 2PhII TARCEVA
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche GANTENERUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII GANTENERUMAB
Therapeutic area: Central Nervous System
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII AVASTIN
Therapeutic area: Cancer
Roche VALCYTE Biodrugs/ Drugs Autoimmune & Inflammation Transplanted organ and tissue status (Excl. complications) 3PhIII VALCYTE
Therapeutic area: Autoimmune & Inflammation
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI VANUCIZUMAB
Therapeutic area: Cancer
Roche ANTI-INFLUENZA A Biodrugs/ Drugs Infections Influenza 2PhII ANTI-INFLUENZA A
Therapeutic area: Infections
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII XELODA
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII KADCYLA
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems Acute myocardial infarction 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Other malignant neoplasms of skin 1PhI DULIGOTUZUMAB
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 1PhI VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of cervix uteri 2PhII AVASTIN
Therapeutic area: Cancer
Roche EM ACTEMAB RA Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII EM ACTEMAB RA
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 3PhIII XELODA
Therapeutic area: Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ZELBORAF
Therapeutic area: Cancer
Roche LEBRIKIZUMAB Biodrugs/ Drugs Respiratory and Pulmonary system Other diseases of upper respiratory tract 2PhII LEBRIKIZUMAB
Therapeutic area: Respiratory and Pulmonary system
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII PERJETA
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche EM RA PRED DEV Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM RA PRED DEV
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche CD40 IMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CD40 IMAB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 2PhII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasms 3PhIII ZELBORAF
Therapeutic area: Cancer
Roche MERICITABINE Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII MERICITABINE
Therapeutic area: Infections
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII PERJETA
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche HCV POL INH PRO Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII HCV POL INH PRO
Therapeutic area: Infections
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and unspecified parts of biliary tract 2PhII GAZYVA
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of brain 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII PERJETA
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Malignant neoplasms of lymphoid haematopoietic + 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche LAMPALIZUMAB Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 3PhIII LAMPALIZUMAB
Therapeutic area: Ophthalmology and optometry
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Other disorders involving the immune mechanism 2PhII ERIVEDGE
Therapeutic area: Autoimmune & Inflammation / Cancer
Roche CIF MEK INH Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CIF MEK INH
Therapeutic area: Cancer
Roche GPC3 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of liver 2PhII GPC3 MAB
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII TASELISIB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII KADCYLA
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Cardiovascular and circulatory systems Other necrotizing vasculopathies 3PhIII MABTHERA
Therapeutic area: Cardiovascular and circulatory systems
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche FORTOVASE Biodrugs/ Drugs Infections HIV disease unspecified 2PhII FORTOVASE
Therapeutic area: Infections
Roche EM MS BIOMARKER Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM MS BIOMARKER
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche HPV16 TI Biodrugs/ Drugs Infections Viral agents as cause of diseases classified to other 2PhII HPV16 TI
Therapeutic area: Infections
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PARSATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII PARSATUZUMAB
Therapeutic area: Cancer
Roche ALECTINIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECTINIB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII KADCYLA
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Pemphigus 3PhIII MABTHERA
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IPATASERTIB
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche HERCEPTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 2PhII HERCEPTIN
Therapeutic area: Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII IGF1R MAB
Therapeutic area: Cancer
TiGenix Cx611 Gene / Cell Therapy Autoimmune & Inflammation
Infections
Severe sepsis 2PhII Cx611
Therapeutic area: Autoimmune & Inflammation / Infections
TiGenix Cx621 Gene / Cell Therapy Autoimmune & Inflammation TBD (Tick-borne diseases) 1PhI Cx621
Therapeutic area: Autoimmune & Inflammation
TiGenix AlloCSC-01 Gene / Cell Therapy Cardiovascular and circulatory systems Acute myocardial infarction 2PhII AlloCSC-01
Therapeutic area: Cardiovascular and circulatory systems
TiGenix Cx611 Gene / Cell Therapy Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII Cx611
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
TiGenix Cx601 Gene / Cell Therapy Autoimmune & Inflammation
Digestive System
Perianal fistula in Crohn disease patients 3PhIII Cx601
Therapeutic area: Autoimmune & Inflammation / Digestive System